Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

Stock Information for NAPC Defense Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NAPC Defense Inc.

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Q32 Bio Sells Complement Inhibitor ADX-097
Akebia Announces Establishment of Rare Kidney Disease Pipeline
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Akebia Therapeutics to Present at Upcoming Investor Conferences
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.